We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sanofi will acquire Cambridge, UK-based biopharmaceutical company Kymab in a potential $1.45bn deal, which will see the French pharma add Kymab’s monoclonal antibody (mAB) KY1005 to its pipeline.